Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Tenofovir Stories

2012-07-11 14:20:33

RESEARCH TRIANGLE PARK, N.C., July 11, 2012 /PRNewswire-USNewswire/ -- Results of the FHI 360 FEM-PrEP HIV-prevention trial reinforce the key role of adherence in HIV-prevention studies and the need to determine better approaches to support adherence in future pre-exposure prophylaxis (PrEP) programs. Despite targeted counseling and support, adherence to the drug regimen was low, suggesting that women in the clinical trial population may have had difficulty adhering to a daily pill regimen....

2012-07-10 22:20:59

LONDON, July 11, 2012 /PRNewswire/ -- Shionogi-ViiV Healthcare LLC today announced that initial results have been received from the Phase III SINGLE (ING114467) study of the investigational integrase inhibitor dolutegravir in treatment-naive adults with HIV-1. The study demonstrated superiority of the dolutegravir-based regimen compared to the single tablet regimen Atripla®. At 48 weeks, 88% of study participants on the dolutegravir regimen were virologically suppressed (<50...

AIDS Drug Could Get Approved This Summer
2012-06-30 06:29:18

redOrbit Staff & Wire Reports - Your Universe Online The fight against AIDS could get some help this summer, as the Food and Drug Administration (FDA) is expected to approve a drug used to prevent the transmission of HIV, the AIDS virus. Made by Gilead Sciences of Foster City, California, Truvada is already widely used in combination with other drugs to treat patients with HIV. To help the approval process, 2 studies have been published in The Lancet which show just how effective...

2012-05-17 12:31:32

Reformulated gel could serve as an anti-HIV product for both vagina and rectum A change in the formulation of tenofovir gel, an anti-HIV gel developed for vaginal use, may make it safer to use in the rectum, suggests a study published online this week in the Journal of Antimicrobial Chemotherapy. In laboratory tests of rectal tissue, researchers from the Microbicide Trials Network (MTN) found that the reformulated gel was less harmful to the lining of the rectum than the original vaginal...

2012-05-16 10:58:17

Pre-birth exposure to the anti-HIV drug tenofovir does not adversely affect pregnancy outcomes and does not increase birth defects, growth abnormalities, or kidney problems in infants born to African women who are HIV positive, supporting the use of this drug during pregnancy, according to a study by a team of international researchers published in this week's PLoS Medicine. The researchers led by Diana Gibb from the MRC Clinical Trials Unit in London, UK, analyzed data collected on...

2012-04-17 10:38:33

No added HIV risk with hormonal contraceptives, 1 study finds: Results presented at Microbicides 2012 An HIV prevention trial that pre-dates the shift to antiretroviral (ARV)-based approaches is nonetheless helping to answer some of the most relevant and topical questions the field is facing today. More than three years after reporting the primary results of HPTN 035, one of the last trials of the so-called first generation microbicides, researchers from the National Institutes of...

2012-04-16 21:35:58

Researchers, activists and funders are meeting this week in Sydney to discuss the state of HIV prevention research. The biennial International Microbicides Conference, which was opened on Sunday evening by the Honorable Tanya Plibersek MP, Australian Minster of Health, is taking place amid renewed optimism about development and delivery of new HIV prevention options with the potential for ending the AIDS epidemic, including anti-retroviral based microbicides and pre-exposure prophylaxis...

2012-03-06 11:23:36

Follow-up study planned to further assess gel's potential as a rectal microbicide to prevent HIV A gel formulation of the antiretroviral drug tenofovir designed specifically for rectal use was found safe and acceptable, according to a Phase I clinical study led by the U.S. National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN), and presented today at the 19th Conference on Retroviruses and Opportunistic Infections (CROI). The results of the study, which included...

2012-01-20 08:30:00

CHICAGO, Jan. 20, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Gilead Sciences, Inc. (Nasdaq: GILD), Bristol-Myers Squibb Company (NYSE: BMY), Inhibitex, Inc. (Nasdaq: INHX), Vertex Pharmaceuticals (Nasdaq: VRTX) and Merck (NYSE: MRK). (Logo:...

2011-12-20 06:00:00

PITTSBURGH, Dec. 20, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited (formerly Matrix Laboratories Limited) has received approval for three antiretroviral (ARV) therapies used to treat HIV/AIDS under the World Health Organization's (WHO) Prequalification of Medicines Programme. The products include: Atazanavir Capsule, 300 mg, Ritonavir Tablet, 100 mg (heat-stable), and Tenofovir Disoproxil Fumarate and Lamivudine Tablet 300...